Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dynein axonemal heavy chain 3 (DNAH3) is a member of the axonemal dynein family, encoding a large microtubule-associated motor protein critical for the movement of motile cilia and flagella[1][2][3][4]. It is involved in generating the force required for ciliary and flagellar beating via ATP hydrolysis, playing an essential role in processes such as sperm motility and respiratory ciliary function[2][4]. DNAH3 is predominantly expressed in the testis, especially in the developing and mature sperm cells, where it is indispensable for proper flagellar assembly and function[3][4][5]. Loss-of-function or biallelic mutations in DNAH3 cause morphological and functional defects in sperm flagella, leading to male infertility phenotypes such as oligoasthenoteratozoospermia, characterized by low sperm count, poor motility, and abnormal morphology[4][5]. Variants in DNAH3 are also implicated in certain cancers, likely through effects on the cytoskeleton and cell motility. There are currently no known drugs that directly target DNAH3, and it is not a typical therapeutic target or drug receptor in clinical practice.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dynein axonemal heavy chain 3 (DNAH3).